CBA Guangzhou Office

Since 1996 when CBA’s founders led the first team to organize lectures and symposiums in Guangzhou, CBA and the Guangzhou Provincial Government had established strong and long-term friendship and partnership.  Then in 2012, CBA’s leadership team visited Guangzhou with a special plan to discuss with the local government, regarding the official establishment of CBA’s branch in China, hoping to help attract overseas projects, talents, investments and IPRs into Guangzhou Economic Development Zone. In July 2013, CBA’s very first office in China – CBA-Guangzhou Office -, was officially founded on the Guangzhou International Bio-Island, with the goal  to serve as a bridge between the U.S. and Chinese biomedical companies and  professionals, and work as a platform for international  technology imports, talent imports and project evaluation. The opening ceremony  was held on July 23rd, 2013 in Guangzhou.

The CBA Guangzhou Office was sponsored by the Guangzhou Nanotides Pharmaceuticals Co., Ltd. Its mission is to advance “Nanotech for Peptides” by structure-based functional peptide screening and nanoparticle-enhanced delivery. Its major goal is to commercialize peptides for drug delivery immediately and to develop novel polypeptide therapeutics for pulmonary fibrosis, diabetes mellitus, and NSCLC in the future.

CBA Tianjin Office

The CBA Tianjin Office was founded in September 2016 at the Tianjin Economic and Technological Development Area. It aims to serve as the platform to bring advanced bio-technologies and professional biopharmaceutical talents from US to China, and to promote biomedical collaborations between US and the Northeastern China.

The CBA Tianjin Office is sponsored by the Tianjin CanSino Biotechnology Inc. (CanSino), and the office set-up received generous support from the Tianjin Municipal Government, Tianjin Office of Overseas Chinese Affairs, and many other local government agencies and organizations.

The Tianjin CanSino Biotechnology Inc. is a biotechnology company dedicated to R&D, manufacturing and commercialization of vaccine products for human use. CanSino’s mission is to develop high value and high quality vaccines for China and other emerging countries at an affordable cost.

CBA Shanghai Office

The CBA Shanghai Office was established in September 2016, located in the Caohejing Pujiang Science Park, Minhang District ofShanghai. Its main focus is to serve the CBA individual and corporate members in China and facilitate the business communications and cooperation between the biopharmaceutical industries in US and China, esp. those in the Eastern China regions. The Shanghai Office also aims to expand CBA’s exposure and impacts in China mainland, and to attract more Chinese members into CBA.

CBA Shanghai office is sponsored by Shanghai Furen Medicine R&D Co., Ltd., a leading research and development company focusing on new therapeutics and new medical technologies. Its parent company, the Furen Medicines Group Co., Ltd., is one of the top 100 pharmaceutical companies in China. Shanghai Furen is supporting many top innovation-driven R&D companies by offering initial and follow-up fundings as well as its world-class research and development facilities via five platforms, including cell therapies, antibody and protein therapeutics, new CNS drugs, generics and other healthcare products. The strategic partnership between CBA and Shanghai Furen will not only benefit both parties, but more importantly, promote deeper and further collaborations among many bio-med research institutes and biopharmaceutical companies in the US and China.